This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments. Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories. Matthew will explore: - Strategies for providing plasmids across all necessary grades, ensuring quality and consistency. - How process standardization can significantly simplify complex supply chains. - The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues. - How these integrated approaches collectively streamline operations and accelerate gene therapy advancements. - His expert insights on the future trajectory of gene therapy.

This episode, 'Translating Promising Drug Candidates from Preclinical Screening to Clinical Trials,' will explore the challenges and successes of moving promising drug candidates from preclinical screening to clinical trials in oncology. Join Dr. Steve Shnyder, Associate Professor at the Institute of Cancer Therapeutics, University of Bradford, as he explores: - The unique challenges in oncology drug development. - Preclinical model limitations and needed innovations. - Translating preclinical insights into effective clinical trial design. - The role of AI and machine learning in overcoming development hurdles. - Real-world case studies of successful oncology drug approvals.

In this episode, we examine how machine learning and artificial intelligence (AI) are becoming essential tools for improving image analysis of 3D samples. These technologies are reshaping research workflows by making analysis faster and more insightful. We speak with Professor Jens Christian Schwamborn, Professor of Cellular and Developmental Biology at the University of Luxembourg, and Professor Christophe Deben, Professor of Tumour Biology and Organoids at the University of Antwerp. They share their perspectives on the current challenges in 3D sample analysis and how AI is helping to solve them - reducing processing time and revealing previously inaccessible information. We'll look at the key reasons behind AI’s growing use in 3D image analysis, identify the limitations of existing imaging technologies, and explore how AI is evolving to handle increasingly complex data. We'll also discuss how the availability of large datasets is accelerating this shift and what breakthroughs AI could enable in the near future.

In this episode, we explore the key challenges hindering the widespread adoption of personalised medicine and discuss how overcoming these barriers could transform the future of healthcare. Featuring insights from Seth Lederman, co-founder, CEO, and Chairman of Tonix Pharmaceuticals, and Steve Gardner, CEO of Precision Life and Chair of the UK Bioindustry Association Genomics Board, this conversation addresses the critical issues shaping the field. Topics include the necessary adaptations in healthcare systems to support this shift, the ethical concerns surrounding patient data privacy and genetic information, and the groundbreaking advancements anticipated in the near future.

In this episode, we will discuss how can we leverage microbiomics to translate gut microbiome findings into new therapeutic options

In this episode, we discuss the history of the AAPS Summer Scientific Forum, highlights from the 2024 event, and its goals for the future.

In this episode, we will discuss the unique biology of tRNA and how it can be leveraged to scale the development of genetic medicines.  This conversation features Michelle Werner, CEO of Alltrna and CEO-Partner at Flagship Pioneering, and Caroline Köhrer, Vice President, Discovery Platform at Alltrna.

In this podcast episode, we will be investigating the key considerations in selecting an antibody for use in antibody drug conjugates (ADCs). Also, we will be discussing the preclinical models used to evaluate the pharmacokinetics and pharmacodynamics of ADCs.  This conversation features Dr Philipp Spycher, CSO and co-founder at Araris Biotech, and Dr Rebecca Boohaker, Director of Oncology at Southern Research.